{"organizations": [], "uuid": "31cdda1bfa5558cc15dcc03e761bf11aad7f62ec", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "https://si.wsj.net/public/resources/images/BN-XN751_2XRrg_TOP_20180219135441.jpg", "site_section": "http://www.wsj.com/xml/rss/3_7014.xml", "section_title": "WSJ.com: US Business", "url": "https://www.wsj.com/articles/trial-tests-ftcs-power-to-referee-drug-makers-fight-against-generics-1519131601", "country": "US", "domain_rank": 387, "title": "Trial Tests FTC’s Power to Referee Drug Makers’ Fight Against Generics", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-20T15:00:00.000+02:00", "replies_count": 0, "uuid": "31cdda1bfa5558cc15dcc03e761bf11aad7f62ec"}, "author": "Peter Loftus", "url": "https://www.wsj.com/articles/trial-tests-ftcs-power-to-referee-drug-makers-fight-against-generics-1519131601", "ord_in_thread": 0, "title": "Trial Tests FTC’s Power to Referee Drug Makers’ Fight Against Generics", "locations": [], "entities": {"persons": [{"name": "abbvie", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "philadelphia", "sentiment": "none"}], "organizations": [{"name": "ftc", "sentiment": "negative"}, {"name": "power to referee drug makers’ fight against generics a", "sentiment": "neutral"}, {"name": "abbvie inc.", "sentiment": "none"}, {"name": "federal trade commission", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "A trial under way in federal court in Philadelphia is testing the power of U.S. competition regulators to crack down on drugmakers’ alleged moves to thwart the sale of low-cost generics.\nThe trial, which began Feb. 7, stems from a 2014 Federal Trade Commission lawsuit accusing AbbVie Inc. of filing baseless patent-infringement lawsuits against two generic-drug companies to delay competition for its testosterone-replacement therapy AndroGel. AbbVie denies the allegations.\n...  ", "external_links": [], "published": "2018-02-20T15:00:00.000+02:00", "crawled": "2018-02-20T23:11:46.011+02:00", "highlightTitle": ""}